Estée Lauder Companies
EL
$107.72
+3.92%
Estée Lauder Companies is a global prestige beauty manufacturer whose portfolio spans skin care (49% of fiscal 2025 sales), makeup (29%), fragrance (17%), and hair care (5%), sold under brands including Estée Lauder, Clinique, M.A.C, La Mer, Jo Malone London, and Aveda across more than 150 countries through department stores, travel retail, specialty beauty retailers, freestanding stores, and e-commerce. It is one of the largest pure-play prestige beauty platforms in the world, with a geographic mix of roughly 31% Americas, 37% EMEA (heavily weighted to travel retail), and 32% Asia-Pacific, giving it unmatched global brand breadth but also concentrated exposure to the challenged department-store and travel-retail channels. The current investor narrative centers on a credible turnaround: after a brutal stretch of negative quarters culminating in a fiscal Q4 2025 net loss of $546 million, the company has posted four consecutive profitable quarters through June 2026, with revenue growth reaccelerating to 6.3% year over year and gross margin recovering to 75.5%. Sentiment was further reset in May 2026 when Estée Lauder walked away from merger talks with Spain's Puig, with investors rewarding the clarity of the standalone turnaround plan, and the August 2026 fiscal Q4 print triggered a sharp re-rating as sales acceleration and margin expansion validated the restructuring thesis. The debate now is whether this is an early-cycle earnings recovery with substantial operating leverage still to come, or a low-quality rebound propped up by cost cuts and easy comparisons against a depressed base.…
EL
Estée Lauder Companies
$107.72
Related headlines
EL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Estée Lauder Companies's 12-month outlook, with a consensus price target around $109.02 and implied upside of +1.2% versus the current price.
Average Target
$109.02
0 analysts
Implied Upside
+1.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $127
Analyst target range
Bulls vs Bears: EL Investment Factors
The bull case currently has the stronger evidence: four consecutive profitable quarters, 6.3% revenue growth, gross margin back to 75.5%, and $1.3 billion of TTM free cash flow represent a genuine inflection, and the market has rewarded it with 27.3% three-month gains and +24.6 points of relative strength. The bear case rests on the quality and durability of that recovery — a 1.2% net margin, 157.9x trailing PE, and 2.43x debt-to-equity mean the earnings base is still thin and highly levered. The single most important tension is whether the margin expansion is structural operating leverage from the restructuring or a cyclical bounce off a depressed base amplified by easy comparisons; if gross margin holds above 75% while revenue grows mid-single digits, the forward PE of 26.6x is defensible, but any deceleration would expose the valuation as premature.
Bullish
- Turnaround validated by margin recovery: Gross margin has recovered to 75.5% in Q4 2026 from 72.0% in the year-ago Q4 2025, and quarterly gross profit rose to $2.737 billion from $2.456 billion. Operating income swung from $141 million to $254 million on essentially flat revenue, showing real cost leverage rather than just top-line help.
- Revenue reaccelerating to 6.3% YoY: Q4 2026 revenue of $3.627 billion grew 6.3% year over year versus $3.411 billion in Q4 2025, a sharp reversal from the prior year's declines. This is the first clear evidence that the four-quarter profitable streak is being driven by demand, not only expense cuts.
- Analyst consensus buy with upside: 28 analysts carry a consensus recommendation of 'buy' (mean 2.27) with an average target of $108.20, implying roughly 3.5% upside from the $104.54 close and a high target of $127 (+21%). The low target of $70 sits near the 52-week low of $66.22, framing a wide but positively skewed distribution.
- Strong momentum and relative strength: The stock is up 27.3% over three months and 37.2% over six months, versus the S&P 500's 2.69% and 7.48% respectively, producing relative strength of +24.6 and +29.7 points. The August 2026 earnings print triggered a single-day jump from $84.27 to $98.01, confirming institutional conviction in the turnaround.
Bearish
- Extreme leverage: D/E of 2.43: Debt-to-equity of 2.43 is very high for a consumer defensive name, and quarterly interest expense of $82-86 million consumes a meaningful share of operating income. In Q4 2026, $84 million of interest expense plus a $358 million net other-expense line turned $254 million of operating income into a $104 million pre-tax loss.
- Valuation stretched on trailing metrics: Trailing PE is 157.9x, price-to-book is 7.52x, and EV/EBITDA is 20.9x, all rich for a company with a 1.2% net margin. The forward PE of 26.6x on $4.25 estimated EPS already prices in a near-full earnings recovery, leaving little room for disappointment.
- Profitability still thin and volatile: Net margin is just 1.21% and ROE is 4.78%, far below what a prestige beauty leader should earn. The company posted a $546 million net loss in Q4 2025 and a $590 million loss in Q2 2025, showing earnings remain highly sensitive to one-time charges and impairments.
- Underperformance versus the market: Despite the recent rally, the stock is down 2.08% year to date and has underperformed the S&P 500 by 14.0 percentage points YTD and 7.5 points over one year. The 52-week range of $66.22 to $121.64 implies a 43.8% max drawdown, underscoring how fragile sentiment remains.
EL Technical Analysis
Beta
1.26
1.26x market volatility
Max Drawdown
-43.8%
Largest decline past year
52-Week Range
$66-$122
Price range past year
Annual Return
+9.2%
Cumulative gain past year
| Period | EL Return | S&P 500 |
|---|---|---|
| 1m | +7.4% | -1.2% |
| 3m | +34.2% | +3.4% |
| 6m | +38.4% | +7.0% |
| 1y | +9.2% | +14.4% |
| ytd | +0.9% | +12.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EL Fundamental Analysis
Quarterly Revenue
$3.6B
2026-06
Revenue YoY Growth
+6.3%
YoY Comparison
Gross Margin
75.5%
Latest Quarter
Free Cash Flow
$1.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EL Overvalued?
PE
157.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 31x~169x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
20.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by leverage and thin profitability. Debt-to-equity of 2.43 and quarterly interest expense of $82-86 million mean roughly a third of Q4 2026's $254 million operating income was consumed by interest, and a $358 million net other-expense line pushed the quarter to a $104 million pre-tax loss despite positive operating income. Net margin of 1.21% and ROE of 4.78% leave almost no cushion, and the payout ratio of 2.79 signals the 1.78% dividend is not covered by current GAAP earnings, creating risk of a dividend reset if the recovery stalls. Revenue concentration adds to this: 37% of sales come from EMEA (travel retail heavy) and 32% from Asia-Pacific, so a single regional shock can overwhelm cost-cut gains.
Market and competitive risks center on valuation compression and channel disruption. At 157.9x trailing earnings, 7.52x book, and 20.9x EV/EBITDA, EL trades at a premium that assumes the turnaround completes; a beta of 1.265 means it amplifies market moves, and the 43.8% max drawdown shows how violently the stock de-rates when growth disappoints. The prestige beauty category faces pressure from specialty multibrand retailers and direct-to-consumer brands encroaching on department-store share, while the abandoned Puig merger in May 2026 removed a potential strategic exit and leaves the standalone plan fully exposed to execution risk. Year-to-date underperformance of 14.0 points versus the S&P 500 also raises sector-rotation risk if investors favor cheaper defensive staples.
In a worst-case scenario, a China/travel-retail demand relapse combines with a gross margin slip back toward the 72.0% seen in Q4 2025, compressing forward EPS below the $4.18 low analyst estimate and forcing multiple contraction from 26.6x toward the high-teens. That would take the stock back toward the $70 analyst low target, roughly -33% from $104.54, and a fuller de-rating to the 52-week low of $66.22 implies a loss of about -37%. The historical max drawdown of 43.8% shows this magnitude of decline is not hypothetical for this name, and with a short ratio of 2.19 there is enough bearish positioning to accelerate a downside move on a single disappointing quarter.